HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. - Wikidata - awgldk - TriplyDB

HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.

HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.

http://www.wikidata.org/entity/Q35893399

about

HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach Predictive biomarkers for Barrett's esophagus: so near and yet so far TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions.Biomarkers of Barrett's esophagus.HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma.Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction.Predictors of progression in Barrett's esophagus: current knowledge and future directions Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma.Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis Her-2/neu testing and therapy in gastroesophageal adenocarcinoma.Clinical implications of molecular changes in pediatric Barrett's esophagus.A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus.A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus.Use of immunohistochemical biomarkers as independent predictor of neoplastic progression in Barrett's oesophagus surveillance: A systematic review and meta-analysis.HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.Molecular Abnormalities in Pediatric Barrett Esophagus: Can We Test for Potential of Neoplastic Progression?Early HER2 dysregulation in gastric and oesophageal carcinogenesis

P2860

Q26741253-FF1E7ECC-60A7-4FF6-AFBD-691159A1E446 Q26780318-331CCD3D-9837-47C2-BF62-5578C68C25E5 Q26849403-503002E6-678C-479B-9CEC-7250B408E4A6 Q34044864-C6486BB6-631E-4D6B-9949-4F644BF844A6 Q34324291-B2021DB7-F9FF-46A9-A26C-1F30F61E4D6E Q34448115-A932940C-5BFA-4940-832C-653D26291653 Q35111575-A90E85E9-CD28-4821-83CD-57029F177415 Q36101895-9B6C63D2-6285-41CF-8063-2C847CACFEFE Q36112574-A3AA1C3C-DE96-4BF1-B9C2-A444FE85B719 Q36127891-FB88C748-411B-4E12-982D-2F6450E917CE Q36666667-C36F8DF4-3EC2-4B8D-B587-64834A46C9E0 Q37033556-ABBE0783-FFE7-4F7A-A169-17AAEDF6F32F Q37824265-89475FF3-3746-4095-81D9-F5BB6FAA2814 Q37988995-575FB93F-0D45-4FC7-9298-D3019A44DD3D Q38925807-7ED3A037-63D7-4CF0-B2E5-6826E916D1DC Q39752612-5D5C93D7-E0F6-4FA8-BD53-5995E344DB08 Q47104584-2D7E382E-2C3E-4618-9F20-E16B29A34AD1 Q53657591-E12FC1CE-1D78-4027-A1FC-E3E9EBB62879 Q57828317-5743B49A-359D-4D42-A79D-1210FC0120B1 Q58003579-5D4135A3-19BC-4BFF-9104-F0FACEC9F7B9

P2860

HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study.

http://www.wikidata.org/entity/Q35893399

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

HER-2 overexpression/amplifica ...... a: a clinico-pathologic study.

@ast

HER-2 overexpression/amplifica ...... a: a clinico-pathologic study.

@en

type

label

HER-2 overexpression/amplifica ...... a: a clinico-pathologic study.

@ast

HER-2 overexpression/amplifica ...... a: a clinico-pathologic study.

@en

prefLabel

HER-2 overexpression/amplifica ...... a: a clinico-pathologic study.

@ast

HER-2 overexpression/amplifica ...... a: a clinico-pathologic study.

@en

P1433

Q35893399-F3D92326-AF5C-4999-943B-A297947311A9

P1476

Q35893399-827769B4-C5D4-4975-9082-E2E3FC401BB2

P2093

Q35893399-00065890-0D98-401E-A005-69928AE472E3

Q35893399-0451E317-4A9C-4A3F-B247-9B7D1152B998

Q35893399-29EE74FA-874E-495E-B8F0-25DC89C89CF3

Q35893399-8B66EC5B-BF55-4379-8B2E-896FD8EF5BFD

Q35893399-C68BFA5D-705B-4678-A32A-26334752F596

Q35893399-D9751617-28EE-4AA3-A64E-4D42EEE5743E

Q35893399-DC90FE67-E88A-4C0D-B523-B2B362AF571C

Q35893399-DFEB522F-4E03-41EF-97E5-6373446B5270

Q35893399-E2451ADE-E9B2-49FC-A35E-88FDF2079586

P2860

Q35893399-166CC5CB-8910-4440-AAE8-985811DD4D79

Q35893399-17C18B78-A61C-47FA-8808-97C0F747BB68

Q35893399-1F432E61-A3BC-4DFC-AB8D-B08D45D429E8

Q35893399-2D55D71E-2FA0-443B-A2AC-DB6682FB77BA

Q35893399-324901DA-7EE6-4B83-ADAB-D88F68391FB5

Q35893399-443131CC-11D5-4169-8CF2-90208E2FAC44

Q35893399-48C65D0F-10C2-470C-A064-487930DACE4E

Q35893399-4C8B15BD-ECB5-4BBB-8B77-15DE12EA4C4D

Q35893399-5CA8855F-C22E-4BE0-AFED-81261516A6E4

Q35893399-6902C697-45E7-4BA7-96EC-8FDBEEB9A460

P304

Q35893399-7E399233-0D4C-4933-A1F2-7E4E03DDAE2D

P31

Q35893399-24C93210-FF4A-488F-9814-FAF10C43A1AA

P356

Q35893399-517FA614-C25F-45B7-82BF-4372AE081BE9

P433

Q35893399-C732F2A7-0ACD-40EA-821C-7619F3E9043E

P478

Q35893399-E8D94B0B-ED05-4F34-833A-16555394B69C

P50

Q35893399-CABD469F-1546-4221-ACE1-65C708E225C0

P577

Q35893399-69F9C636-1217-41CA-AC54-45BC0818C241

P5875

Q35893399-1C67C198-52CF-48A9-9A53-80624B9CA453

P698

Q35893399-A3E7698C-A76C-4818-A6FA-BBB77FA5CEA7

P921

Q35893399-068D0EA6-C5F9-4FB3-9EBE-1610AF7CDDD2

Q35893399-BDB0A7C4-1F60-448C-AB55-203E9553F816

P932

Q35893399-332319FF-199D-4971-8458-905275109EA7

P356

J.1582-4934.2008.00517.X

P1433

Journal of Cellular and Molecular Medicine

P1476

HER-2 overexpression/amplifica ...... ma: a clinico-pathologic study

@en

P2093

Domenico Della Casa

http://www.w3.org/2001/XMLSchema#string

Elisa Rossi

http://www.w3.org/2001/XMLSchema#string

Gabrio Bassotti

http://www.w3.org/2001/XMLSchema#string

Guido Missale

http://www.w3.org/2001/XMLSchema#string

Luigi Minelli

http://www.w3.org/2001/XMLSchema#string

Paolo Cengia

http://www.w3.org/2001/XMLSchema#string

Renzo Cestari

http://www.w3.org/2001/XMLSchema#string

Salvatore Grisanti

http://www.w3.org/2001/XMLSchema#string

Vincenzo Villanacci

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Global cancer statistics, 2002

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk

Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.

Circumferential endoscopic resection of Barrett's esophagus with high-grade dysplasia or early adenocarcinoma.

The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

Phases of biomarker development for early detection of cancer.

Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience.

P304

3826-3833

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1582-4934.2008.00517.X

http://www.w3.org/2001/XMLSchema#string

P433

9B

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Michela Buglione

P577

2008-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24206882

http://www.w3.org/2001/XMLSchema#string

P698

19292734

http://www.w3.org/2001/XMLSchema#string

P921

P932

4516530

http://www.w3.org/2001/XMLSchema#string